دورية أكاديمية
Combination Strategies to Improve Targeted Radionuclide Therapy.
| العنوان: | Combination Strategies to Improve Targeted Radionuclide Therapy. |
|---|---|
| المؤلفون: | Chan TG; Department of Oncology, University of Oxford, Oxford, United Kingdom., O'Neill E; Department of Oncology, University of Oxford, Oxford, United Kingdom., Habjan C; Department of Oncology, University of Oxford, Oxford, United Kingdom., Cornelissen B; Department of Oncology, University of Oxford, Oxford, United Kingdom bart.cornelissen@oncology.ox.ac.uk. |
| المصدر: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2020 Nov; Vol. 61 (11), pp. 1544-1552. Date of Electronic Publication: 2020 Oct 09. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Reston, VA : Society of Nuclear Medicine Original Publication: [Chicago, Ill.] : S.N. Turiel & Assoc. |
| مواضيع طبية MeSH: | Neoplasms/*radiotherapy, Cell Cycle/drug effects ; Combined Modality Therapy ; DNA Damage ; DNA Repair/drug effects ; HSP90 Heat-Shock Proteins/antagonists & inhibitors ; Hedgehog Proteins/antagonists & inhibitors ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; NAD/metabolism ; Octreotide/analogs & derivatives ; Octreotide/therapeutic use ; Organometallic Compounds/therapeutic use ; Radiation-Sensitizing Agents/pharmacology ; Radiation-Sensitizing Agents/therapeutic use ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Topoisomerase Inhibitors/pharmacology ; Topoisomerase Inhibitors/therapeutic use |
| مستخلص: | In recent years, targeted radionuclide therapy (TRT) has emerged as a promising strategy for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionizing radiation to tumors in a targeted manner, reducing the dose that healthy tissues are exposed to. Existing TRT strategies include the use of 177 Lu-DOTATATE, 131 I-metaiodobenzylguanidine, Bexxar, and Zevalin, clinically approved agents for the treatment of neuroendocrine tumors, neuroblastoma, and non-Hodgkin lymphoma, respectively. Although promising results have been obtained with these agents, clinical evidence acquired to date suggests that only a small percentage of patients achieves complete response. Consequently, there have been attempts to improve TRT outcomes through combinations with other therapeutic agents; such strategies include administering concurrent TRT and chemotherapy, and the use of TRT with known or putative radiosensitizers such as poly(adenosine diphosphate ribose) polymerase and mammalian-target-of-rapamycin inhibitors. In addition to potentially achieving greater therapeutic effects than the respective monotherapies, these strategies may lead to lower dosages or numbers of cycles required and, in turn, reduce unwanted toxicities. As of now, several clinical trials have been conducted to assess the benefits of TRT-based combination therapies, sometimes despite limited preclinical evidence being available in the public domain to support their use. Although some clinical trials have yielded promising results, others have shown no clear survival benefit from particular combination treatments. Here, we present a comprehensive review of combination strategies with TRT reported in the literature to date and evaluate their therapeutic potential. (© 2020 by the Society of Nuclear Medicine and Molecular Imaging.) |
| References: | Oncotarget. 2017 Jul 7;8(40):69105-69124. (PMID: 28978184) Clin Nucl Med. 2017 Nov;42(11):e457-e466. (PMID: 28872545) Lancet Oncol. 2019 Aug;20(8):e434-e442. (PMID: 31364595) Cancer Res. 1997 Apr 15;57(8):1529-36. (PMID: 9108456) Cell. 2015 May 21;161(5):1215-1228. (PMID: 26000489) J Nucl Med. 2018 Dec;59(12):1843-1849. (PMID: 29959213) Nature. 2017 Mar 2;543(7643):65-71. (PMID: 28199314) Mod Pathol. 2017 Apr;30(4):587-598. (PMID: 28059098) Cancer Res. 1997 May 15;57(10):1929-33. (PMID: 9157987) Nat Rev Cancer. 2006 Oct;6(10):789-802. (PMID: 16990856) Mol Cancer Ther. 2006 Feb;5(2):411-7. (PMID: 16505116) Prostate. 2009 Jan 1;69(1):92-104. (PMID: 18942092) J Nucl Med. 2016 Nov;57(11):1805-1810. (PMID: 27363833) Anticancer Drugs. 2014 May;25(5):502-11. (PMID: 24335716) Cancer Res. 2005 Oct 15;65(20):9194-9. (PMID: 16230379) Cancer Biother Radiopharm. 2015 Aug;30(6):261-9. (PMID: 26181854) Vascul Pharmacol. 2019 Feb;113:20-26. (PMID: 30336218) Lancet Oncol. 2019 Mar;20(3):408-419. (PMID: 30738780) Crit Rev Oncol Hematol. 2005 Oct;56(1):47-60. (PMID: 16039868) Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11. (PMID: 21052661) Radiother Oncol. 2017 Sep;124(3):488-495. (PMID: 28595752) Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):113-122. (PMID: 32383093) J Nucl Med. 2015 Aug;56(8):1239-45. (PMID: 26045312) Cancer Res. 2006 Sep 15;66(18):9211-20. (PMID: 16982765) Oncotarget. 2017 Sep 28;8(48):84426-84433. (PMID: 29137436) Clin Nucl Med. 2019 May;44(5):e329-e335. (PMID: 30932975) Cell Commun Signal. 2020 Mar 12;18(1):43. (PMID: 32164764) Int J Radiat Oncol Biol Phys. 1992;22(3):515-8. (PMID: 1310495) J Nucl Med. 2021 Feb;62(2):228-231. (PMID: 32646877) Front Med (Lausanne). 2015 Mar 17;2:12. (PMID: 25853132) Neuroendocrinology. 2019;108(3):256-264. (PMID: 30352433) Nature. 2005 Apr 14;434(7035):917-21. (PMID: 15829967) Biomolecules. 2015 Oct 16;5(4):2589-618. (PMID: 26501335) J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S. (PMID: 15653647) J Clin Oncol. 2015 May 20;33(15):1666-73. (PMID: 25870087) Br J Radiol. 2008 Oct;81 Spec No 1:S28-35. (PMID: 18819996) Radiat Res. 2011 Feb;175(2):214-24. (PMID: 21268715) Clin Breast Cancer. 2015 Feb;15(1):e55-62. (PMID: 25445418) Sci Rep. 2020 Jun 23;10(1):10196. (PMID: 32576907) Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):157-163. (PMID: 32057994) Theranostics. 2019 Jul 9;9(17):4841-4848. (PMID: 31410185) Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):980-990. (PMID: 31912256) Cancer Biother Radiopharm. 2004 Jun;19(3):378-87. (PMID: 15285886) Cancer Res. 2013 Jan 1;73(1):12-8. (PMID: 23149918) Curr Top Med Chem. 2020;20(32):2959-2969. (PMID: 32101125) EJNMMI Res. 2014 May 30;4:21. (PMID: 24995150) Arch Pathol Lab Med. 2013 Apr;137(4):552-7. (PMID: 23544944) Br J Cancer. 2010 Jul 13;103(2):186-95. (PMID: 20588277) Mol Cancer Ther. 2013 Oct;12(10):2043-54. (PMID: 23873849) Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138. (PMID: 30232539) Cell. 2017 Mar 9;168(6):960-976. (PMID: 28283069) Oncotarget. 2018 May 15;9(37):24693-24706. (PMID: 29872498) J Mol Endocrinol. 2015 Apr;54(2):137-47. (PMID: 25612765) Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):743-8. (PMID: 18188559) Leuk Lymphoma. 2013 Sep;54(9):1996-2002. (PMID: 23256542) Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621. (PMID: 28676700) PLoS One. 2010 Jan 05;5(1):e8581. (PMID: 20052416) N Engl J Med. 2017 Jan 12;376(2):125-135. (PMID: 28076709) Semin Nucl Med. 2020 Mar;50(2):133-140. (PMID: 32172798) Int J Immunopathol Pharmacol. 2017 Dec;30(4):341-352. (PMID: 28988508) Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721-728. (PMID: 31758224) Neuroendocrinology. 2019;109(4):333-345. (PMID: 31167197) Biochim Biophys Acta Mol Cell Res. 2018 Sep;1865(9):1293-1311. (PMID: 29936127) EJNMMI Res. 2015 Dec;5(1):62. (PMID: 26553049) Cell Death Dis. 2014 Oct 02;5:e1437. (PMID: 25275598) Radiat Res. 1968 Mar;33(3):620-43. (PMID: 4867897) Clin Cancer Res. 2010 Feb 1;16(3):898-911. (PMID: 20103674) BMC Cancer. 2017 Aug 8;17(1):528. (PMID: 28789624) Nature. 2015 Apr 16;520(7547):373-7. (PMID: 25754329) Front Pharmacol. 2018 Nov 19;9:1331. (PMID: 30510514) J Nucl Med. 2017 Feb;58(2):288-292. (PMID: 27688470) Mol Cancer Ther. 2017 Jan;16(1):16-24. (PMID: 28062703) Br J Cancer. 2008 Nov 4;99(9):1375-9. (PMID: 18797460) J Nucl Med. 2019 Jan;60(1):65-70. (PMID: 29748236) Radiat Environ Biophys. 1995 Jun;34(2):79-83. (PMID: 7652155) Theranostics. 2016 Jul 18;6(11):1821-32. (PMID: 27570553) Cancer Chemother Pharmacol. 2013 Mar;71(3):663-70. (PMID: 23370660) J Biol Chem. 2002 Oct 18;277(42):39858-66. (PMID: 12176997) Oncogene. 2004 Jan 29;23(4):873-82. (PMID: 14661061) EJNMMI Res. 2020 Apr 25;10(1):41. (PMID: 32335736) Biochim Biophys Acta. 2008 Apr;1785(2):96-132. (PMID: 18068131) Clin Cancer Res. 2005 Nov 1;11(21):7929-37. (PMID: 16278418) J Nucl Med. 2019 Sep;60(9):1293-1300. (PMID: 30850485) Cancer Biother Radiopharm. 2012 Nov;27(9):561-9. (PMID: 23078020) J Cancer Res Clin Oncol. 2019 Jan;145(1):137-152. (PMID: 30357520) Mol Cancer Ther. 2020 Jan;19(1):26-38. (PMID: 31582533) Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1588-1590. (PMID: 31069454) Theranostics. 2019 Oct 16;9(25):7948-7960. (PMID: 31695808) Drug Des Devel Ther. 2017 Oct 13;11:3009-3017. (PMID: 29075104) Cancer Res. 2008 Sep 15;68(18):7466-74. (PMID: 18794134) Endocr Relat Cancer. 2019 Feb 1;26(4):437-449. (PMID: 30730850) Int J Oncol. 1996 May;8(5):991-6. (PMID: 21544456) Oncotarget. 2017 Aug 2;8(40):68641-68653. (PMID: 28978144) |
| معلومات مُعتمدة: | 23970 United Kingdom CRUK_ Cancer Research UK; MR/P018661/1 United Kingdom MRC_ Medical Research Council |
| فهرسة مساهمة: | Keywords: combination therapy; radiotherapy; targeted radionuclide therapy |
| المشرفين على المادة: | 0 (HSP90 Heat-Shock Proteins) 0 (Hedgehog Proteins) 0 (Immune Checkpoint Inhibitors) 0 (Organometallic Compounds) 0 (Radiation-Sensitizing Agents) 0 (Topoisomerase Inhibitors) 0U46U6E8UK (NAD) AE221IM3BB (lutetium Lu 177 dotatate) EC 2.7.11.1 (TOR Serine-Threonine Kinases) RWM8CCW8GP (Octreotide) |
| تواريخ الأحداث: | Date Created: 20201010 Date Completed: 20210309 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC8679619 |
| DOI: | 10.2967/jnumed.120.248062 |
| PMID: | 33037092 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-5667 |
|---|---|
| DOI: | 10.2967/jnumed.120.248062 |